Related Experiment Video
Updated: Aug 6, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the
Elizabeth Sokol1, Arlene Naranjo2, Lulu Chen2
1Division of Pediatric Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract:
Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse. Prospective data regarding long-term outcomes following this therapy have not been reported. Five-year progression-free survival (PFS) and overall survival (OS) for patients treated with chemoimmunotherapy were 22.6% ± 6.6% and 54.7% ± 7.7%, respectively. Patients with early disease progression following treatment on ANBL1221 tended to have been diagnosed with high-risk neuroblastoma at a younger age than those without early disease progression. A subset of chemoimmunotherapy-treated patients survived ≥2 years, but most all received additional therapy.